Aarti Drugs Limited — Q4 FY26
Aarti Drugs reported Q4 FY26 consolidated revenue of ₹721.1 crore (+6% YoY) and EBITDA of ₹96.6 crore (13.4% margin).
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
Sikar plant utilization to reach 50% by March 2026, 75% next quarter
Sikar facility expected to ramp to 50% utilization in Q4 FY26 and 75% in the subsequent quarter, with full utilization within 12 months.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1